immunotherapy
| 2 min read
With so many cancer patients not responding to these immunotherapies, researchers are looking for new ways to boost their efficacy.
| 8 min read
By starting with T cells from healthy donors, Allogene is manufacturing off-the-shelf CAR T cell therapies that patients don’t have to wait for.
| 4 min read
Metabolic conditioning is emerging as a powerful strategy to enhance the potency, persistence, and manufacturability of next-generation cell therapies, providing new hope for hard to treat cancers.
| 4 min read
Another death linked to Sarepta’s gene therapy, a promising glioblastoma trial, a rejection for Replimune, and more led the news this week.
| 4 min read
A novel immunotherapy targets the liver to promote tolerance to allergens in mice, promising durable allergy relief without the risk of severe reactions.
| 5 min read
IO Biotech’s two-pronged cancer vaccine targets tumors and the suppressive immune cells around them, demonstrating promising results in metastatic melanoma.
| 4 min read
Cancer researchers in biotech and pharma highlight the clinical trials and developments they’re most excited about.
| 3 min read
Omalizumab could be a better treatment for children with food allergies compared to oral immunotherapy, mainly due to fewer side effects.
| 7 min read
A targeted interleukin-12 gene therapy plus chemotherapy increased survival in advanced ovarian cancer, setting the stage for a new first-line drug.
| 5 min read
From advances in graft versus host disease treatment to updates on H5N1 and Duchenne muscular dystrophy research, the DDN editors break down the news this week.
